RT Journal Article SR Electronic T1 Preference-Based Utility Scores for Adverse Events Associated With the Treatment of Gynecologic Cancers JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1157 OP 1165 DO 10.1097/IGC.0b013e318299e2a6 VO 23 IS 6 A1 Elizabeth L. Jewell A1 Michael Smrtka A1 Gloria Broadwater A1 Fidel Valea A1 Debra M. Davis A1 Kimberly C. Nolte A1 Renea Valea A1 Evan R. Myers A1 Laura J. Havrilesky YR 2013 UL http://ijgc.bmj.com/content/23/6/1157.abstract AB Objective Our goals were to (1) define a set of descriptive health states related to adverse events (AEs) associated with gynecologic cancer treatment with radical surgery and chemoradiation and (2) derive a set of quality of life–related utility scores corresponding to these health states.Methods We developed a list of health states for grade 3/4 AEs related to gynecologic cancer treatment. Using the visual analog scale score and time trade-off (TTO) methods, valuation of each health state was obtained through interviews of 60 volunteers (15 cervical cancer survivors treated with surgery and/or chemoradiation and 45 women without a cancer diagnosis). Health states were ranked by mean/median TTO scores. Wilcoxon rank sum test was used to compare central tendencies related to patient and volunteer characteristics.Results Patients and volunteers agreed on their preference rankings, with highest preference given to infection (median TTO = 1.0) and thrombosis (median TTO = 0.97). Lowest preference was assigned to radiation proctitis (median TTO = 0.87) and gastrointestinal fistula formation (median TTO = 0.83). Utility scores for the majority of health states were not significantly associated with age, race, parity, patient or volunteer status, history of abnormal Pap smear, stage of cervical cancer diagnosis, or personal experience of a serious treatment-related AE.Conclusions This study helps establish preferences and quality-of-life utility scores for health states related to toxicities from surgery, radiation, and chemotherapy for gynecologic cancer treatment. Such information can be used to inform medical decision making/counseling and may be applied to future comparative effectiveness models in which radical surgery and/or chemoradiation are considered.